HLA-B and toxic epidermal necrolysis: Although having HLA-B*15:02 increases the risk of CBZ/OXC induced SJS/TEN by up to >700-fold compared to non-carriers, the vast majority of patients with HLA-B*15:02 (95%–99%) do not develop SJS/TEN from CBZ/OXC (Amstutz et al., 2014).